• NurOwn, Now in Phase 3 Trial, Shows Potential in ALS Patients with Rapid Progression, BrainStorm’s CMO Says in Interview
  • Poor Tolerability Leads to Failure of ALS Therapy Candidate Tirasemtiv in Phase 3 Trial
  • ALS Patients’ Lung-function Decline Scores Can Predict Breathing Failure, Study Reports
  • Radicava and Its Decisive Phase 3 Trial Among Presentations at ALS/MND Meeting This Weekend
  • Stem Cell Treatment Targeting Spinal Cord Won’t Slow ALS, Researchers Say
  • Takeda and Montreal Neurological Institute Team Up to Research New ALS Therapies
  • Join the ALS Boogie Board Club
  • VA Adds Radicava to its National Formulary for ALS Patients
  • Fight Depression by Keeping Watch on Ourselves and Others
  • NY Students Advance to Siemens Competition Finals with Discovery that Could Aid ALS Research
  • Rare Mutations Can Interact With Related Proteins to Promote ALS Progression, Study Shows
  • ALS Association’s Incoming CEO Urges Insurers to Expand Narrow Coverage of Radicava